Autophagy-related proteins Beclin-1 and LC3 predict cetuximab efficacy in advanced colorectal cancer

Table 5 Survival analysis of 45 patients with advanced colorectal cancer treated by cetuximab-containing chemotherapy

Clinical factors	n (%)	MOS (mo)	P value
Gender			0.93
Male	29 (64.4)	52.5
Female	16 (35.6)	33
Age (yr), median (range)
Risk group (40-60)	23 (51.1)	40	0.38
Non-riskgroup ( ≤ 40 or > 60)	22 (48.9)	35
Family history of tumor			0.23
No	36 (80.0)	40
Yes	9 (20.0)	42
Tumor site			0.88
Colon	32 (71.1)	42
Rectum	13 (28.9)	42
Primary clinical stage			< 0.01
II	5 (11.1)	137
III	15 (33.3)	43
IV	25 (55.6)	22
Histological grade			0.049
Well and moderate diff	34 (75.6)	43
Poor diff	11 (24.4)	23
Beclin-1 expression			0.75
Low	15 (33.3)	42.5
High	30 (66.7)	35
LC3 expression			0.27
Low	17 (37.8)	42.5
High	28 (62.2)	33
KRAS status			0.73
Wild type	28 (71.8)	43
Mutation	11 (28.2)	22

MOS: Median overall survival; Diff: Differentiation.